Effects of Flutamide on [Methyl-3H]-Choline Uptake in Human Prostate Cancer-3 Cells: A Pilot Study

Current Therapeutic Research - Clinical and Experimental

Volumn 68, Issue 4, 2007, Pages 226-241

  Al Saeedi, Fatma ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

methyl 3H choline; flutamide; PC 3 cells; PET; radiopharmaceuticals; tumor

Indexed keywords

CARBON 11; CHOLINE; FLUTAMIDE; METHYL CHOLINE H 3; THIAZOLE; TRITIUM; TRYPAN BLUE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PLASMA CLEARANCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; RADIOACTIVITY;

EID: 34748868977     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2007.08.003     Document Type: Article

References (58)

1. Allal A., Dulguerov P., Allaoua M., et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 20 (2002) 1398-1404
2. Lichy M., Bachert P., Henze M., et al. Monitoring individual response to brain-tumour chemotherapy: Proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy. Neuroradiology 46 (2004) 126-129
3. Higashi K., Clavo A., and Wahl R. In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 34 (1993) 773-779
4. Kubota K., Ishiwata K., Kubota R., et al. Tracer feasibility for monitoring tumor radiotherapy: A quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, L-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67. J Nucl Med 32 (1991) 2118-2123
5. Akhurst T., Downey R., Ginsberg M., et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg. 73 (2002) 259-264 discussion 264-266
6. Krak N., Hoekstra O., and Lammertsma A. Measuring response to chemotherapy in locally advanced breast cancer: Methodological considerations. Eur J Nucl Med Mol Imaging 31 Suppl 1 (2004) S103-S111
7. Bender H., Bangard N., Metten N., et al. Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. Hybridoma 18 (1999) 87-91
8. Liu I., Zafar M., Lai Y., et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57 (2001) 108-111
9. Hara T., Kosaka N., and Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39 (1998) 990-995
10. Hobson R., and Beynon A. Preliminary quantitative microradiography study into the distribution of bone mineralization within the basal bone of the human edentulous mandible. Arch Oral Biol 42 (1997) 497-503
11. de Jong I., Pruim J., Elsinga P., Vaalburg W., and Mensink H. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol. 44 (2003) 32-38 discussion 38-39
12. Schmidt J. Clinical diagnosis of prostate cancer. Cancer 70 Suppl 1 (1992) 221-224
13. In: Cotran R., Kumar V., and Collins T. (Eds). Pathologic Basis of Disease. 6th ed. (1999), WB Saunders, Philadelphia, Pa
14. Yagoda A., and Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71 Suppl 3 (1993) 1098-1109
15. Beato M. Gene regulation by steroid hormones. Cell 56 (1989) 335-344
16. Labrie F. Mechanism of action and pure antiandrogenic properties of flutamide. Cancer 72 Suppl 12 (1993) 3816-3827
17. Brufsky A., Fontaine-Rothe P., Berlane K., et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 49 (1997) 913-920
18. A1-Saeedi F., Welch A., and Smith T. [methyl-3H]Choline incorporation into MCF7 tumour cells: Correlation with proliferation. Eur J Nucl Med Mol Imaging 32 (2005) 660-667
19. World Medical Association Declaration of Helsinki. Principles for Medical Research Involving Human Subjects [WMA Web site]. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Available at:. http://www.wma.net/e/policy/b3.htm Accessed June 2006
20. Bligh E., and Dyer W. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37 (1959) 911-917
21. Kotzerke J., Prang J., Neumaier B., et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 27 (2000) 1415-1419
22. Zheng Q., Gardner T., Raikwar S., et al. [llC]Choline as a PET biomarker for assessment of prostate cancer tumor models. Bioorg Med Chem 12 (2004) 2887-2893
23. Catalona W. Management of cancer of the prostate. N Engl J Med 331 (1994) 996-1004
24. Tilley W., Wilson C., Marcelli M., and McPhaul M. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 50 (1990) 5382-5386
25. Kaighn M., Narayan K., Ohnuki Y., et al. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17 (1979) 16-23
26. Ware J., Paulson D., Mickey G., and Webb K. Spontaneous metastasis of cells of the human prostate carcinoma cell line PC-3 in athymic nude mice. J Urol 128 (1982) 1064-1067
27. Kozlowski J., Fidler I., Campbell D., et al. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res. 44 (1984) 3522-3529
28. Pizzi H., Gladu J., Carpio L., et al. Androgen regulation of parathyroid hormone-related peptide production in human prostate cancer cells. Endocrinology 144 (2003) 858-867
29. Wang Y., Shao C., Shi C., et al. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism. Asian J Androl 7 (2005) 375-380
30. Baratta M., Grolli S., Poletti A., et al. Role of androgens in proliferation and differentiation of mouse mammary epithelial cell line HC11. J Endocrinol. 167 (2000) 53-60
31. 18F]fluoro-D-glucose in tumor imaging with positron emission tomography. Mol Imaging Biol 4 (2002) 267-273
32. Ackerstaff E., Pflug B., Nelson J., and Bhujwalla Z. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 61 (2001) 3599-3603
33. Fulham M., Bizzi A., Dietz M., et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: Clinical relevance. Radiology 185 (1992) 675-686
34. DeGrado T., Coleman R., Wang S., et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res 61 (2001) 110-117
35. Inaloz H., Ketani M., Inaloz S., et al. The effects of sialoadenectomy and flutamide on skin development. Clin Exp Obstet Gynecol 27 (2000) 231-234
36. Brass A., Barnard J., Patai B., et al. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Cancer Res 55 (1995) 3197-3203
37. Mabjeesh N., Willard M., Frederickson C., et al. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res. 9 (2003) 2416-2425
38. Cook S., and Wakelam M. Analysis of the water-soluble products of phosphatidyl-choline breakdown by ion-exchange chromatography. Bombesin and TPA (12-0-tetradecanoylphorbol 13-acetate) stimulate choline generation in Swiss 3T3 cells by a common mechanism. Biochem J. 263 (1989) 581-587
39. Joseph T., Wooden R., Bryant A., et al. Transformation of cells overexpressing a tyrosine kinase by phospholipase D1 and D2. Biochem Biophys Res Commun 289 (2001) 1019-1024
40. Lu Z., Hornia A., Joseph T., et al. Phospholipase D and RalA cooperate with the epidermal growth factor receptor to transform 3Y1 rat fibroblasts. Mol Cell Biol 20 (2000) 462-467
41. Kiss Z. Regulation of phospholipase D by protein kinase C. Chem Phys Lipids 80 (1996) 81-102
42. Jaken S. Protein kinase C isozymes and substrates. Curr Opin Cell. Biol. 8 (1996) 168-173
43. Lundberg A., and Weinberg R. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18 (1998) 753-761
44. Jimenez B., del Peso L., Montaner S., et al. Generation of phosphorylcholine as an essential event in the activation of Raf-1 and MAP-kinases in growth factors-induced mitogenic stimulation. J Cell Biochem 57 (1995) 141-149
45. Montalvo L., Carmena M., Bolanos O., et al. Effects of the antiandrogen flutamide on the expression of protein kinase C isoenzymes in LNCaP and PC3 human prostate cancer cells. Biosci Rep. 24 (2004) 11-21
46. Kawashima H., Tanaka T., Cheng J., et al. Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cells. Urol Res 32 (2004) 406-410
47. Levenson A., and Jordan V. MCF-7: The first hormone-responsive breast cancer cell line. Cancer Res 57 (1997) 3071-3078
48. Migliaccio A., Di Domenico M., Green S., et al. Phosphorylation on tyrosine of in vitro synthesized human estrogen receptor activates its hormone binding. Mol Endocrinol. 3 (1989) 1061-1069
49. Griffiths K., and International Prostate Health Council Study Group. Estrogens and prostatic disease. Prostate 45 (2000) 87-100
50. Denti L., Pasolini G., Cortellini P., et al. Effects of androgen suppression by gonadotropin-releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: Focus on lipoprotein(a). Clin Chem 42 (1996) 1176-1181
51. Bonkhoff H., Fixemer T., Hunsicker I., and Remberger K. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol. 155 (1999) 641-647
52. Lau K., LaSpina M., Long J., and Ho S. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial ceils: Regulation by methylation and involvement in growth regulation. Cancer Res 60 (2000) 3175-3182
53. Weihua Z., Makela S., Andersson L., et al. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci US A 98 (2001) 6330-6335
54. Kim I., Kim B., Seong do H., et al. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res. 62 (2002) 5365-5369
55. Rohlff C., Blagosklonny M., Kyle E., et al. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21 (wafl/cipl). Prostate 37 (1998) 51-59
56. Kiss Z., and Crilly K. Tamoxifen inhibits uptake and metabolism of ethanolamine and choline in multidrug-resistant, but not in drug-sensitive, MCF-7 human breast carcinoma cells. FEBS Lett 360 (1995) 165-168
57. Nunez-Vergara L., Farias D., Bollo S., and Squella J. An electrochemical evidence of free radicals formation from flutamide and its reactivity with endo/xenobiotics of pharmacological relevance. Bioelectrochemistry 53 (2001) 103-110
58. Omezzine A., Chater S., Mauduit C., et al. Long-term apoptotic cell death process with increased expression and activation of caspase-3 and -6 in adult rat germ cells exposed in utero to flutamide. Endocrinology 144 (2003) 648-661